Hadile Ounallah-Saad

Hadile Ounallah-Saad is an experienced professional in the field of biotechnology and pharmaceuticals, currently serving as the Head of Innovation - Early Stage Pipeline at Clexio Biosciences since April 2022. In addition to this role, Hadile is an active member of the 8400 Health Network since January 2019. Previously, Hadile held the position of VP R&D at CannAssure, focusing on controlled medical cannabis, and co-founded Touch Brain, where efforts were directed towards therapeutics for early-stage Parkinson's disease. Earlier experience includes serving as an R&D executive at N2B and a postdoctoral researcher at the University of Haifa, specializing in Alzheimer's disease. Hadile holds an MBA from Bar-Ilan University and a PhD in Neurobiology from The Hebrew University of Jerusalem, complemented by a Master’s and Bachelor’s degree in related fields from esteemed institutions.